Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of TAK-625 in Japanese patients with Alagille syndrome
jRCT2051220098Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of maralixibat in Alagille syndrome (ALGS), sponsored by Takeda. Primary endpoint: Change in fasting serum bile acid levels from Week 18 to Week 22. Started Jan 2023; status: completed.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on jRCT2051220098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220098.